Treatment
Investigational products were ferroquine 100 mg capsules (Sanofi, France) and artefenomel 300/400/600 mg granules formulation (Sanofi, France) presented in a sachet with alpha tocopherol polyethylene glycol 1000 succinate formulation and sucrose. Dose selection aimed to characterize the anti-malarial contribution of artefenomel to the combination. Artefenomel has been evaluated to doses up to 1200 mg with no safety concerns, and a wide range of doses (0–1000 mg) was selected to evaluate the exposure–response. The 400 mg ferroquine dose was selected as a sub-therapeutic dose so as not to mask the contribution of artefenomel. Details of the dose selection methods are in Additional file 